3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
3
Active not recruiting
3
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Head & Neck
3
Conditions
Endometrial Neoplasms
6
Neoplasms
5
Colonic Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Uterine Cervical Neoplasms
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Carcinosarcoma
1
Neoplasms, Second Primary
1
Locally Advanced Rectal Cancer (LARC)
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
pembrolizumab
61
Cisplatin
37
Carboplatin
23
Radiotherapy
21
Cetuximab
19
Magnetic Resonance Spectroscopy
18
Paclitaxel
17
Specimen Handling
13
Docetaxel
12
Fluorouracil
11
Nivolumab
10
tislelizumab
9
Surgical Procedures, Operative
8
Radiotherapy, Intensity-Modulated
7
Radiation
7
cemiplimab
6
Standard of Care
6
Platinum
6
Chemoradiotherapy
6
Biopsy
6
1,2-diaminocyclohexaneplatinum II citrate
6
toripalimab
5
Drug Therapy
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Taxes
4
Ipilimumab
4
Immunotherapy
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Squamous Cell Carcinoma of Head and Neck
×
dostarlimab
×
Clear all
NCT06256588
2026-05-26
JADE
GlaxoSmithKline
Phase 3
Recruiting
864 enrolled
NCT07408063
2026-04-29
BeeHive
University Health Network, Toronto
Phase 2
Recruiting
30 enrolled
NCT04681469
2022-08-04
PRIME
Gruppo Oncologico del Nord-Ovest
Phase 2
Recruiting
49 enrolled